Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 389

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 389
---
. Holders of Class B
common stock are entitled to one vote for each share. On July 3, 2023, the Sponsor delivered notice of conversion of an aggregate of
4,596,250 shares of Class B common stock into an equal number of shares of Class A common stock. As of December 31, 2023 and 2022, there
were 0 and 4,596,250 shares of Class B common stock issued and outstanding.

Prior to the consummation of an initial business
combination, only holders of shares of Class B common stock will have the right to vote on the election of directors. Holders of
shares of Class A common stock and shares of Class B common stock will vote together as a single class on all other matters
submitted to a vote of stockholders.

<div align='center'>F-43

PHOENIX BIOTECH ACQUISITION CORP.

NOTES TO FINANCIAL STATEMENTS

DECEMBER 31, 2023</div>

Preferred stock — The Company
is authorized to issue 1,000,000 shares of preferred stock with such designations, voting and other rights and preferences
as may be determined from time to time by the Company’s board of directors. As of December 31, 2023 and 2022, there were no shares
of preferred stock issued or outstanding.

Warrants — At December 31,
2023 and 2022, there were 8,750,000 Public Warrants and 442,500 Private Placement Warrants outstanding. The Public Warrants will become
exercisable 30 days after the completion of a business combination. No warrants will be exercisable for cash unless the Company
has an effective and current registration statement covering the common stock issuable upon exercise of the warrants and a current prospectus
relating to such common stock.

Notwithstanding the foregoing, if a registration
statement covering the common stock issuable upon exercise of the Public Warrants is not effective within a specified period following
the consummation of a business combination, warrant holders may, until such time as there is an effective registration statement and
during any period when the Company shall have failed to maintain an effective registration statement, exercise warrants on a cashless
basis pursuant to the exemption provided by Section 3(a)(9) of the Securities Act, provided that such exemption is available. If
that exemption, or another exemption, is not available, holders will not be able to